The government-funded rollout involves PainChek’s “world’s first” smartphone pain assessment and monitoring device which uses facial recognition software to accurately assess pain in people who are non-verbal.
PainChek (ASX:PCK) says Ward MM already has a team of expert clinical pharmacists working across residential aged care in Australia, currently delivering medication advisory services to reduce medication related harm within residential aged care.
“This partnership will help fast track the PainChek government funded program with WardMM providing their skilled resources to support the PainChek roll out across the more than 2000 aged care homes in Australia” said Philip Daffas, CEO of PainChek.
“Our joint goal is to deliver the PainChek solution and pain medication training to the nurses and carers who look after the 100,000 Australian aged care residents with dementia within a one-year timeframe.”
With the PainChek rollout, engagement of the residential aged care facilities, marketing of the training program and co-ordination of the sessions will be centralised through PainChek, with Ward MM delivering up to 350 PainChek residential aged care training sessions - and Ward MM implementing a “train the trainer” program co-ordinated via its 30 clinical pharmacists.
Ward MM CEO, Fiona Rhody-Nicoll said; “We are thrilled to be partnering with PainChek to ensure an optimal roll out of this powerful technology nationally. We see great opportunity for the functionality of PainChek to support clinical teams to make better informed decisions, particularly for those who are unable to articulate their pain.
“The PainChek technology will allow our own team to translate resident pain-assessment data and insights into actionable medication recommendations for GPs via the Residential Medication Management Review process, delivering a more pro-active and integrated level of care for residents of aged care facilities.”